Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Application of nanoparticles in the therapeutic management of endometrial cancer

Ke D., Li W., Chen Q., Luo L., Wang Y., Meng F.

Narrative Review on Systemic / IV, published in Eur J Med Res (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Eur J Med Res (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41491970
PMCID
PMC12871008
DOI
10.1186/s40001-025-03623-y
Citations
2

Abstract (original English)

The management of endometrial cancer (EC) remains challenging due to metastatic risk, therapeutic resistance, and the modest durability of standard regimens. Nanotechnology offers a promising avenue to overcome these limitations by enhancing tumor-selective drug delivery, enabling controlled release, and facilitating multimodal approaches that integrate therapy and imaging. This review systematically summarizes recent advances in nanoparticle applications for EC, focusing on strategies that target key molecular drivers, such as TP53, PI3K/PTEN, and immune checkpoints, and evaluates localized administration routes such as vaginal delivery. Preclinical studies, including the demonstration of JX06-loaded nanoparticles combined with metformin achieving approximately 86% viability inhibition in patient-derived EC cells, underscore the potential of nanoformulations to improve intracellular delivery and therapeutic efficacy. However, current research remains constrained by its reliance on limited cell lines and immunodeficient animal models. Clinically validated active targeting efficacy has yet to be established in EC, and translational progress is further hindered by the inconsistent enhanced permeability and retention (EPR) effect, accelerated blood clearance upon repeated dosing, as well as manufacturing and regulatory challenges. Through rational design of the targeting functiona

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansEndometrial NeoplasmsAntineoplastic AgentsDrug Delivery SystemsFemaleNanoparticles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research